Verastem logo

Verastem

VSTM | NASDAQ
Chart Builder DCF Calculator
$7.70
-$0.48 (-5.87%)
At close: Nov 16, 2026, 4:00 PM ET
$7.78
+$0.08 (+1.04%)
After-hours: Nov 16, 2026, 7:30 PM ET
-5.87%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
44
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #422/1021 (Top 41%)

Key Statistics

Market Data

Market Cap $970.31M
1D Range
7.69 8.30
52W Range
3.45 10.64

Valuation (TTM)

PE -4.16
PB 96.06
EV/EBITDA -5.24

Valuation (NTM)

Forward PE N/A
Forward PEG 0.11
Price Target $16.00
Loading financial charts...

Profile

Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-676...

Sector Healthcare
Industry Biotechnology
Employees 102
IPO Date Jan 27, 2012
Fiscal Year January - December

Latest News

Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance

11 hours ago · marketbeat.com

Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path

5 days ago · marketbeat.com

Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans

7 days ago · marketbeat.com

Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans
What Verastem (VSTM) Said on Its Q3 Earnings Call

10 days ago · marketbeat.com

What Verastem (VSTM) Said on Its Q3 Earnings Call

Earnings

Latest Earnings
Nov 5, 2026
EPS
-$0.74
Miss -56.45%
REV
$24.01M
Miss -9.63%
Next Earnings
Mar 3, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$16.00
Upside
+107.79%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.